New Zealand's pharmaceutical regulator has approved two psychiatrists to prescribe pharmaceutical-grade MDMA to patients suffering from severe post-traumatic stress disorder, marking a significant shift in mental health treatment policy.
Definium Therapeutics announced its experimental LSD-based pill significantly reduced anxiety symptoms in a late-stage study, meeting the trial's main goal. The results mark the company's second major win in two months and sent shares up more than 20% in premarket trading.
Compass Pathways reported results from a pivotal study showing its psilocybin-based therapy demonstrated long-lasting benefits for treatment-resistant depression, though investor reaction was mixed as shares fell nearly 10% on the data.
